Multiple Myeloma Perspective

 
 
  • Top News From ASCO 2019: Slideshow Highlights include potentially practice-changing data on immunotherapy for head and neck cancer, as well new data for breast, lung, prostate and pancreatic cancer.
  • EHA 2019 Read clinically focused news coverage of key developments from EHA 2019
  • 'Mind-boggling' IO Data, Plus New Combos, Targets for NSCLC   Drs West, Aggarwal, and Patel discuss the 'mind-boggling,' 'humbling,' and 'amazing' advances in survival statistics and targeted therapies for NSCLC presented at ASCO 2019.
  • IWMF 2019 Read clinically focused news coverage of key developments from IWMF 2019
  • Down the Medicare Part D Rabbit Hole   With greater Medicare Part D coverage resulting in higher out-of-pocket costs for patients, it seems that covering the 'donut hole' has only helped to reveal the drug-pricing rabbit hole.
  • BSH 2019 Read clinically focused news coverage of key developments from BSH 2019
  • Multiple Myeloma: Fast Forward   City of Hope experts report on advances in disease detection as well as promising treatment strategies poised to extend survival for patients with myeloma.
  • Multiple Myeloma: Recurrent Issues   City of Hope experts address the current best strategies and emerging treatments, including CAR T-cell therapy, for patients with relapsed and refractory myeloma.
  • Four Major Developments in Multiple Myeloma: ASH 2018   Joseph Mikhael discusses important new treatment options for multiple myeloma therapy as profiled at ASH 2018.
  • Top News From ASH 2018: Slideshow Hot topics include practice change data on chronic lymphocytic leukemia, validation of the durability of CAR T cells, and a new standard of care in myeloma.
  • Multiple Myeloma: Relapse-Ready   City of Hope oncologists discuss optimal choices for treating patients with relapsed disease and report on emerging options that are changing the field.
  • Hard Lessons From Year 1 of Oncology Fellowship Loss of autonomy. Practicing in areas of medicine without good evidence. Providing end-of-life care. Oncology fellowship comes with its own unique set of tough lessons.
  • Multiple Myeloma: Tolerable Transplant   Hematologists at City of Hope discuss strategies to improve the tolerability of stem cell transplant in patients with multiple myeloma.
  • Multiple Myeloma: Taking Control   Experts at City of Hope discuss factors that affect choice of initial therapy in multiple myeloma, including election of early autologous stem cell transplant.
  • EHA 2018 Read clinically focused news coverage of key developments from EHA 2018
  • Multiple Myeloma: Options for Better Outcomes   Leading oncologists from the City of Hope Medical Center discuss targeted therapies and immunotherapies, including CAR T cells, that are redefining treatment of patients with relapsed multiple myeloma.
  • Quantifying Cancer Risk in Patients With Glomerular Diseases Dr Desai reviews a paper that presents a useful guide in quantifying cancer risk in patients with glomerular diseases.
  • Immunotherapy Combinations Show Promise for Blood Cancers Immunotherapy combinations hold great promise for treating hematologic cancers, but the approach is not without risk.
  • Multiple Myeloma: The Clone Wars   A growing understanding of normal cell biology and the evolving patterns of cancer clones is contributing to more individualized treatment in multiple myeloma.
  • Multiple Myeloma: On the Horizon   In "On the Horizon," the Mayo team reports on developments in immunotherapies and emerging techniques that are poised to change the management practices of multiple myeloma, including a discussion of how new insights in myeloma cell biology may ultimately cure this disease.